Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palatin LeuTech Diagnostic Cost-Effectiveness Analysis Under Way

Executive Summary

Palatin Technologies is conducting a cost-effectiveness analysis to support use of LeuTech to aid in the diagnosis of equivocal appendicitis.

You may also be interested in...



Palatin/Mallinckrodt Leutech

"Complete review" letter issued by FDA for radiolabeled monoclonal imaging agent, Palatin announces Sept. 28. The letter requests additional manufacturing and process validation data prior to approval. Palatin's contract manufacturer for the biologic is DSM. The BLA for the indication of the diagnosis of equivocal appendicitis was filed Nov. 22, 1999 and recommended by an advisory committee in July (1"The Pink Sheet" July 24, p. 32)

Palatin/Mallinckrodt Leutech

"Complete review" letter issued by FDA for radiolabeled monoclonal imaging agent, Palatin announces Sept. 28. The letter requests additional manufacturing and process validation data prior to approval. Palatin's contract manufacturer for the biologic is DSM. The BLA for the indication of the diagnosis of equivocal appendicitis was filed Nov. 22, 1999 and recommended by an advisory committee in July (1"The Pink Sheet" July 24, p. 32)

LeuTech Studies In Neutropenic Patients Suggested By FDA Committee

Palatin and co-development partner Mallinckrodt should conduct studies with LeuTech to verify efficacy in neutropenic patients and to ensure that the radiolabeled monoclonal antibody imaging agent does not damage white blood cells, FDA's Medical Imaging Drugs Advisory Committee suggested during a July 10 meeting.

Related Content

UsernamePublicRestriction

Register

PS036383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel